Reduction in Acquisition Time and Improvement in Image Quality in T2-Weighted MR Imaging of Musculoskeletal Tumors of the Extremities Using a Novel Deep Learning-Based Reconstruction Technique in a Turbo Spin Echo (TSE) Sequence

Tomography. 2022 Jul 6;8(4):1759-1769. doi: 10.3390/tomography8040148.

Abstract

Background: The aim of this study was to assess the technical feasibility and the impact on image quality and acquisition time of a deep learning-accelerated fat-saturated T2-weighted turbo spin echo sequence in musculoskeletal imaging of the extremities. Methods: Twenty-three patients who underwent MRI of the extremities were prospectively included. Standard T2w turbo inversion recovery magnitude (TIRMStd) imaging was compared to a deep learning-accelerated T2w TSE (TSEDL) sequence. Image analysis of 23 patients with a mean age of 60 years (range 30−86) was performed regarding image quality, noise, sharpness, contrast, artifacts, lesion detectability and diagnostic confidence. Pathological findings were documented measuring the maximum diameter. Results: The analysis showed a significant improvement for the T2 TSEDL with regard to image quality, noise, contrast, sharpness, lesion detectability, and diagnostic confidence, as compared to T2 TIRMStd (each p < 0.001). There were no differences in the number of detected lesions. The time of acquisition (TA) could be reduced by 52−59%. Interrater agreement was almost perfect (κ = 0.886). Conclusion: Accelerated T2 TSEDL was technically feasible and superior to conventionally applied T2 TIRMStd. Concurrently, TA could be reduced by 52−59%. Therefore, deep learning-accelerated MR imaging is a promising and applicable method in musculoskeletal imaging.

Keywords: accelerated turbo spin echo MRI; artificial intelligence; deep learning; musculoskeletal imaging; musculoskeletal tumors.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Artifacts
  • Deep Learning*
  • Extremities
  • Humans
  • Magnetic Resonance Imaging / methods
  • Middle Aged
  • Musculoskeletal Diseases*
  • Neoplasms*

Grants and funding

This research received no external funding.